(3-Bromo-phenyl)-(7,8-dimethoxy-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine | 833451-10-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: (3-Bromo-phenyl)-(7,8-dimethoxy-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine
• 英文别名: N-(3-bromophenyl)-8,9-dimethoxypyrimido[4,5-b][1,4]benzoxazepin-4-amine
• CAS: 833451-10-8
• 化学式: C₁₉H₁₅BrN₄O₃
• 分子量: 427.257
• InChiKey: OCMKRUYIZIFJRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  77.9
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (3-Bromo-phenyl)-(7,8-dimethoxy-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 生成 (3-Bromo-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine
  参考文献：
  名称：

  Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase

  摘要：

  Novel tricyclic derivatives containing an oxazepine, thiazepine, or diazepine ring were studied for their EGFR tyrosine kinase inhibitory activity. While the oxazepines were in general more potent than thiazepines, the diazepines displayed somewhat different structure-activity relationships. Moreover, the diazepines, in contrast to the oxazepines, showed appreciable inhibitory activity against the KDR tyrosine kinase. Furthermore, both oxazepines and diazepines demonstrated significant ability to inhibit autophosphorylation of EGFR in DiFi cells (generally, IC50 values in the single-digit micromolar to submicromolar range). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.031
• 作为产物：
  描述：

  N4-(3-bromophenyl)-6-chloropyrimidine-4,5-diamine 、 2-羟基-4,5-二甲氧基苯甲醛 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (3-Bromo-phenyl)-(7,8-dimethoxy-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine
  参考文献：
  名称：

  Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors

  摘要：

  A novel class of pyrimido[4,5-b]-1,4-benzoxazepines is described as inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. Two compounds display potent EGFR inhibitory activity of less than 1 mu M in cellular phosphorylation assays (IC50 0.47-0.69 mu M) and are highly selective against a small kinase panel. Such compounds demonstrate anti-EGFR activity within a class that is different from any known EGFR inhibitor scaffolds. They also provide a basis for the design of kinase inhibitors with the desired selectivity profile. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.018

文献信息

• Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase
  作者：Leon Smith、Wai C. Wong、Alexander S. Kiselyov、Sabina Burdzovic-Wizemann、Yunyu Mao、Yongjiang Xu、Matthew A.J. Duncton、Ki Kim、Evgueni L. Piatnitski、Jacqueline F. Doody、Ying Wang、Robin L. Rosler、Daniel Milligan、John Columbus、Chris Balagtas、Sui Ping Lee、Andrey Konovalov、Yaron R. Hadari

  DOI：10.1016/j.bmcl.2006.07.031

  日期：2006.10

  Novel tricyclic derivatives containing an oxazepine, thiazepine, or diazepine ring were studied for their EGFR tyrosine kinase inhibitory activity. While the oxazepines were in general more potent than thiazepines, the diazepines displayed somewhat different structure-activity relationships. Moreover, the diazepines, in contrast to the oxazepines, showed appreciable inhibitory activity against the KDR tyrosine kinase. Furthermore, both oxazepines and diazepines demonstrated significant ability to inhibit autophosphorylation of EGFR in DiFi cells (generally, IC50 values in the single-digit micromolar to submicromolar range). (c) 2006 Elsevier Ltd. All rights reserved.
• [EN] EGFR TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE EGFR
  申请人：IMCLONE SYSTEMS INC

  公开号：WO2005009384A2

  公开（公告）日：2005-02-03

  The invention encompasses compounds that inhibit, modulate, or regulate kinases, compositions that contain kinase inhibiting compounds, and methods of treating kinase-dependent diseases and conditions in subjects in need of such treatment. Also, the invention encompasses methods of making compounds that inhibit, modulate or regulate kinases.
• Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors
  作者：Leon Smith、Evgueni L. Piatnitski、Alexander S. Kiselyov、Xiaohu Ouyang、Xiaoling Chen、Sabina Burdzovic-Wizemann、Yongjiang Xu、Ying Wang、Robin L. Rosler、Sheetal N. Patel、Hui-Hsien Chiang、Daniel L. Milligan、John Columbus、Wai C. Wong、Jacqueline F. Doody、Yaron R. Hadari

  DOI：10.1016/j.bmcl.2005.12.018

  日期：2006.3

  A novel class of pyrimido[4,5-b]-1,4-benzoxazepines is described as inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. Two compounds display potent EGFR inhibitory activity of less than 1 mu M in cellular phosphorylation assays (IC50 0.47-0.69 mu M) and are highly selective against a small kinase panel. Such compounds demonstrate anti-EGFR activity within a class that is different from any known EGFR inhibitor scaffolds. They also provide a basis for the design of kinase inhibitors with the desired selectivity profile. (C) 2005 Elsevier Ltd. All rights reserved.